The Pharmacoeconomics of Cognitive Enhancers in Moderate to Severe Alzheimer's Disease

Author： Cappell Jaclyn Herrmann Nathan Cornish Stephen Lanctôt Krista L.

ISSN： 1172-7047

Source： CNS Drugs, Vol.24, Iss.11, 2010-11, pp. : 909-927

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cognitive enhancers provide some benefits in patients with moderate to severe Alzheimer's disease

Drugs & Therapy Perspectives, Vol. 27, Iss. 4, 2011-04 ,pp. : 9-15

Adis International

Access to resources Recommend Favorite

Pharmacological treatment in moderate-to-severe Alzheimer's disease

By Hsiung Ging-Yuek Robin Feldman Howard H

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 15, 2008-10 ,pp. : 2575-2582

Informa Healthcare

Access to resources Recommend Favorite

Spotlight on Memantine in Moderate to Severe Alzheimer's Disease†

By McKeage Kate

Drugs & Aging, Vol. 27, Iss. 2, 2010-02 ,pp. : 177-179

Adis International

Access to resources Recommend Favorite

Memantine: A Pharmacoeconomic Review of its Use in Moderate-to-Severe Alzheimer's Disease

By Plosker Greg L. Lyseng-Williamson Katherine A.

PharmacoEconomics, Vol. 23, Iss. 2, 2005-01 ,pp. : 193-206

Adis International

Access to resources Recommend Favorite

Is memantine a breakthrough in the treatment of moderate-to-severe Alzheimer’s disease?

By Doggrell Sheila

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 10, 2003-10 ,pp. : 1857-1860

Informa Healthcare

Access to resources Recommend Favorite